163 related articles for article (PubMed ID: 32320427)
21. The BCL6 proto-oncogene suppresses p53 expression in germinal-centre B cells.
Phan RT; Dalla-Favera R
Nature; 2004 Dec; 432(7017):635-9. PubMed ID: 15577913
[TBL] [Abstract][Full Text] [Related]
22. Reducing VDAC1 expression induces a non-apoptotic role for pro-apoptotic proteins in cancer cell differentiation.
Arif T; Krelin Y; Shoshan-Barmatz V
Biochim Biophys Acta; 2016 Aug; 1857(8):1228-1242. PubMed ID: 27080741
[TBL] [Abstract][Full Text] [Related]
23. Sprouty2 enhances the tumorigenic potential of glioblastoma cells.
Park JW; Wollmann G; Urbiola C; Fogli B; Florio T; Geley S; Klimaschewski L
Neuro Oncol; 2018 Jul; 20(8):1044-1054. PubMed ID: 29635363
[TBL] [Abstract][Full Text] [Related]
24. BCL6--regulated by AhR/ARNT and wild-type MEF2B--drives expression of germinal center markers MYBL1 and LMO2.
Ding J; Dirks WG; Ehrentraut S; Geffers R; MacLeod RA; Nagel S; Pommerenke C; Romani J; Scherr M; Vaas LA; Zaborski M; Drexler HG; Quentmeier H
Haematologica; 2015 Jun; 100(6):801-9. PubMed ID: 25769544
[TBL] [Abstract][Full Text] [Related]
25. Differential expression of miR16 in glioblastoma and glioblastoma stem cells: their correlation with proliferation, differentiation, metastasis and prognosis.
Tian R; Wang J; Yan H; Wu J; Xu Q; Zhan X; Gui Z; Ding M; He J
Oncogene; 2017 Oct; 36(42):5861-5873. PubMed ID: 28628119
[TBL] [Abstract][Full Text] [Related]
26. B-cell Lymphoma 6 (BCL6): From Master Regulator of Humoral Immunity to Oncogenic Driver in Pediatric Cancers.
McLachlan T; Matthews WC; Jackson ER; Staudt DE; Douglas AM; Findlay IJ; Persson ML; Duchatel RJ; Mannan A; Germon ZP; Dun MD
Mol Cancer Res; 2022 Dec; 20(12):1711-1723. PubMed ID: 36166198
[TBL] [Abstract][Full Text] [Related]
27. Isolinderalactone regulates the BCL-2/caspase-3/PARP pathway and suppresses tumor growth in a human glioblastoma multiforme xenograft mouse model.
Hwang JY; Park JH; Kim MJ; Kim WJ; Ha KT; Choi BT; Lee SY; Shin HK
Cancer Lett; 2019 Feb; 443():25-33. PubMed ID: 30503550
[TBL] [Abstract][Full Text] [Related]
28. Dual mTORC1/2 blockade inhibits glioblastoma brain tumor initiating cells in vitro and in vivo and synergizes with temozolomide to increase orthotopic xenograft survival.
Luchman HA; Stechishin OD; Nguyen SA; Lun XQ; Cairncross JG; Weiss S
Clin Cancer Res; 2014 Nov; 20(22):5756-67. PubMed ID: 25316808
[TBL] [Abstract][Full Text] [Related]
29. miR-221/222 confers radioresistance in glioblastoma cells through activating Akt independent of PTEN status.
Li W; Guo F; Wang P; Hong S; Zhang C
Curr Mol Med; 2014 Jan; 14(1):185-95. PubMed ID: 24295494
[TBL] [Abstract][Full Text] [Related]
30. NKG2D-Dependent Antitumor Effects of Chemotherapy and Radiotherapy against Glioblastoma.
Weiss T; Schneider H; Silginer M; Steinle A; Pruschy M; Polić B; Weller M; Roth P
Clin Cancer Res; 2018 Feb; 24(4):882-895. PubMed ID: 29162646
[No Abstract] [Full Text] [Related]
31. Clinical Significance of
Ting CY; Chang KM; Kuan JW; Sathar J; Chew LP; Wong OJ; Yusuf Y; Wong L; Samsudin AT; Pana MNBM; Lee SK; Gopal NSR; Puri R; Ong TC; Bahari SK; Goh AS; Teoh CS
Int J Med Sci; 2019; 16(4):556-566. PubMed ID: 31171907
[No Abstract] [Full Text] [Related]
32. Blockade of TGF-β signaling by the TGFβR-I kinase inhibitor LY2109761 enhances radiation response and prolongs survival in glioblastoma.
Zhang M; Kleber S; Röhrich M; Timke C; Han N; Tuettenberg J; Martin-Villalba A; Debus J; Peschke P; Wirkner U; Lahn M; Huber PE
Cancer Res; 2011 Dec; 71(23):7155-67. PubMed ID: 22006998
[TBL] [Abstract][Full Text] [Related]
33. IL-6-induced Bcl6 variant 2 supports IL-6-dependent myeloma cell proliferation and survival through STAT3.
Tsuyama N; Danjoh I; Otsuyama K; Obata M; Tahara H; Ohta T; Ishikawa H
Biochem Biophys Res Commun; 2005 Nov; 337(1):201-8. PubMed ID: 16188230
[TBL] [Abstract][Full Text] [Related]
34. The Expanding Role of the BCL6 Oncoprotein as a Cancer Therapeutic Target.
Cardenas MG; Oswald E; Yu W; Xue F; MacKerell AD; Melnick AM
Clin Cancer Res; 2017 Feb; 23(4):885-893. PubMed ID: 27881582
[TBL] [Abstract][Full Text] [Related]
35. Aspirin Affects Tumor Angiogenesis and Sensitizes Human Glioblastoma Endothelial Cells to Temozolomide, Bevacizumab, and Sunitinib, Impairing Vascular Endothelial Growth Factor-Related Signaling.
Navone SE; Guarnaccia L; Cordiglieri C; Crisà FM; Caroli M; Locatelli M; Schisano L; Rampini P; Miozzo M; La Verde N; Riboni L; Campanella R; Marfia G
World Neurosurg; 2018 Dec; 120():e380-e391. PubMed ID: 30144594
[TBL] [Abstract][Full Text] [Related]
36. MiR-338-5p sensitizes glioblastoma cells to radiation through regulation of genes involved in DNA damage response.
Besse A; Sana J; Lakomy R; Kren L; Fadrus P; Smrcka M; Hermanova M; Jancalek R; Reguli S; Lipina R; Svoboda M; Slampa P; Slaby O
Tumour Biol; 2016 Jun; 37(6):7719-27. PubMed ID: 26692101
[TBL] [Abstract][Full Text] [Related]
37. H1/pHGFK1 nanoparticles exert anti-tumoural and radiosensitising effects by inhibition of MET in glioblastoma.
Zhang W; Duan R; Zhang J; Cheung WKC; Gao X; Zhang R; Zhang Q; Wei M; Wang G; Zhang Q; Mei PJ; Chen HL; Kung H; Lin MC; Shen Z; Zheng J; Zhang L; Yao H
Br J Cancer; 2018 Feb; 118(4):522-533. PubMed ID: 29348487
[TBL] [Abstract][Full Text] [Related]
38. Analysis of cellular and molecular antitumor effects upon inhibition of SATB1 in glioblastoma cells.
Frömberg A; Rabe M; Oppermann H; Gaunitz F; Aigner A
BMC Cancer; 2017 Jan; 17(1):3. PubMed ID: 28049521
[TBL] [Abstract][Full Text] [Related]
39. miR-10a inhibits cell proliferation and promotes cell apoptosis by targeting BCL6 in diffuse large B-cell lymphoma.
Fan Q; Meng X; Liang H; Zhang H; Liu X; Li L; Li W; Sun W; Zhang H; Zen K; Zhang CY; Zhou Z; Chen X; Ba Y
Protein Cell; 2016 Dec; 7(12):899-912. PubMed ID: 27815824
[TBL] [Abstract][Full Text] [Related]
40. Key concepts in glioblastoma therapy.
Bartek J; Ng K; Bartek J; Fischer W; Carter B; Chen CC
J Neurol Neurosurg Psychiatry; 2012 Jul; 83(7):753-60. PubMed ID: 22396442
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
